Treatment Options

Radiation Therapy

Radiation therapy is an alternative for the treatment of early prostate cancer, and is often used in the treatment of regionally advanced prostate cancer.

Hoag Family Cancer Institute’s radiation oncology program is another example of its commitment to excellence in personalized prostate cancer treatment. The entire first floor of the cancer institute is dedicated to radiation oncology, where its highly specialized team of medical experts delivers the latest in state-of-the-art radiation therapy to patients.

The most progressive options available for prostate cancer patients include the use of seed-implant brachytherapy. For patients with more advanced prostate cancer, and sometimes as an adjunct to surgery, image guided IMRT using VMAT or tomotherapy is available.


SpaceOAR® hydrogel is the first FDA cleared spacing device to protect the rectum in men undergoing radiation therapy for prostate cancer. Hoag is the first hospital in Southern California, and west of Mississippi, to offer this revolutionary product. Learn more.

Hoag’s radiation oncology program offers a full spectrum of leading-edge radiation treatment options. Visit us for a complete list of radiation oncology services.


Surgery is a vital component in the successful treatment of prostate cancer. Hoag Family Cancer Institute medical team includes experienced surgeons and the latest techniques and technology in the surgical management of prostate cancer.

Increasingly, prostatectomies are being performed via robot-assisted laparoscopy to minimize the extent of the surgery. Hoag surgeons utilize the da Vinci® Si HD™ Surgical System to perform robotic minimally invasive radical prostatectomy. Technological advantages, which include a high-definition optical magnification system and endo-wrist capability, afford a post-operative recovery during which patients experience less pain, less blood loss and quicker return to normal activities. Other potential benefits may include a faster return of urinary continence and sexual function.

Jeffrey Yoshida, M.D., Hoag Urologic Cancer Program Director and fellowship-trained urologic surgeon, is an expert in robotic surgery and has performed more than 1,000 robotic prostatectomies.

Survival Rates

The superior care provided to Hoag prostate cancer patients is most clearly illustrated by having a relative five-year survival rate of 100 percent since the early 1990s.

Hoag was a leader in the use of prostate specific antigen to screen for prostate cancer. This is one of the reasons that more than 90 percent of Hoag prostate cancer patients have only localized disease at the time a diagnosis of prostate cancer is made.

Treatment of Metastatic Disease

Although it is uncommon to detect metastatic prostate cancer at the time of diagnosis, many men eventually develop metastatic prostate cancer, typically in the bones.

Hormonal therapy is usually effective initially, and systemic chemotherapy is typically used in patients who develop hormone-refractory prostate cancer. Increasingly, local therapies are being used to eliminate certain sites of metastatic prostate cancer.

For patients with small numbers of metastases to the liver, surgical resection, radiofrequency ablation, cryoablation and tomotherapy are all treatment options, in addition to systemic therapy or intrahepatic chemotherapy.

Isolated lung metastases may be treated by surgical resection, preferably video-assisted thoracic surgery, radiofrequency ablation, cryoablation or radiation therapy. Bone metastases are typically treated with radiation therapy, whereas brain metastases can usually be effectively treated by Gamma Knife.

With the availability of all these treatment options, the outlook for patients with metastatic cancer is more hopeful than ever.

Multidisciplinary Urologic Cancer Case Conferences

Hoag's multidisciplinary urologic oncology cancer case conferences provide collaborative care planning for prostate cancer patients. This twice-monthly cancer case conference brings together a multidisciplinary team of prostate cancer specialists, including urologists, medical oncologists, radiation oncologists, radiologists, pathologists, nurses and support staff.